Merrimack Pharmaceuticals, Inc. (MACK) ended last trading session with a change of 0.96 percent. It trades at an average volume of 4.05M shares versus 1.35M shares recorded at the end of last trading session. The share price of $3.17 is at a distance of 12.01 percent from its 52-week low and down -64.86 percent versus its peak. The company has a market cap of $399.07M and currently has 125.89M shares outstanding. The share price is currently 0.08 percent versus its SMA20, -26.55 percent versus its SMA50, and -41.42 percent versus its SMA200. The stock has a weekly performance of 3.59 percent and is -22.3 percent year-to-date as of the recent close.

On Jan. 18, 2017 Merrimack Pharmaceuticals, Inc. (MACK) announced that Richard Peters, M.D., Ph.D., has been appointed as the Companys President and Chief Executive Officer, effective February 6, 2017, at which time he will also be appointed to the Merrimack Board of Directors. Dr. Peters will join Merrimack from his current role at Sanofi Genzyme, where he serves as Senior Vice President and Head of Global Rare Diseases. He replaces Gary Crocker, Chairman and Interim President and CEO, who guided the Company during the recent restructuring process and search for a permanent CEO and will remain Chairman of the Board.

MannKind Corporation (MNKD) recently recorded -4.25 percent change and currently at $0.54 is 31.98 percent away from its 52-week low and down -75.84 percent versus its peak. It has a past 5-day performance of -15.76 percent and trades at an average volume of 5.54M shares. The stock has a 1-month performance of -17.78 percent and is -15.01 percent year-to-date as of the recent close. There were about 498.94M shares outstanding which made its market cap $269.98M. The share price is currently -17.65 percent versus its SMA20, -15.12 percent versus its SMA50, and -34.44 percent versus its SMA200.

Feb. 01, 2017 MannKind Corporation (MNKD), a fully integrated biopharmaceutical company focusing on the discovery and development of therapeutic products for patients with diseases such as diabetes, announced the launch of a new Titration Pack containing 60 4 unit cartridges, 60 8 unit cartridges and 60 12 unit cartridges of Afrezza (insulin human) Inhalation Powder.

This new package is intended to simplify physician prescribing of Afrezza and allow patients greater dose flexibility in managing their diabetes, while potentially reducing the cost burden of multiple copays.

Go here to read the rest:
Two Biotechnology Names Are Hot: Merrimack Pharmaceuticals, Inc. (MACK), MannKind Corporation (MNKD) - The Independent Republic